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ABSTRACT Lithium salts are used in the treatment of mania and as prophy-
laxis against manic depressive disorder. The aim of these studies was the in vitro
investigation of the effect of lithium on phospholipids of human erythrocyte
membranes. Erythrocytes were treated with lithium for 1 h. Phospholipids
phosphatidylinositol (PI), phosphatidylserine (PS), phosphatidylethanolamine
(PE), and phosphatidylocholine (PC) were separated from erythrocyte ghosts
anddeterminedbyHPLC.Bloodsamplesfromhealthyadultswereinvestigated.
A very strong decrease in PC content in erythrocyte membranes due to lithium
in vitro treatment was found, as well as a statistically signiﬁcant increase in PI
content.
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INTRODUCTION
Lithium salts are used in the treatment of mania and as prophylaxis against manic
depressive disorder (Goodwin and Jamison 1990). Lithium is normally present in the body
at trace concentrations and is toxic at higher concentrations. In therapeutic treatment, it
is dosed in concentrations below 2 mM (Romano et al. 1995). A long period of treatment
with lithium causes lesions to the gastroenteric tube, the nervous system, and kidneys. The
therapeutic activity of lithium is supposed to be caused by lithium inhibition of inositol
phosphatases, especially the inositol monophosphatase (Manji et al. 1995). Lithium also
reduces brain concentrations of prostaglandin E2 and cyclogenase 2 (Rapoport and Bosetti
2002), as well as decreases phospholipase A2 activity (Rapoport and Bosetti 2002; Chang
and Jones 1998). Most investigations concerning the lithium effect explain its therapeutic
effect. However, the high ability of lithium to inhibit numerous enzymes may also be a
reason for unexpected side effects.
EXPERIMENTAL
HPLC analysis was done with a Merck Hitachi liquid chromatograph with a diode array
detector (model L-4500, Tokyo Japan). A Superspher Si 60 column (250 × 4 mm) was
applied. Phospholipids standards—phosphatidylinositol (porcine liver), phosphatidylser-
ine (bovine brain), phosphatidylethanolamine (porcine liver), and phosphatidylcholine
(porcineliver)(LarodanAB,Sweden)wereused.Butylatedhydroxytoluene(BHT)(analytical
grade Sigma-Aldrich) as well as sodium phosphate buffer-1 (osmolality 310 mmol/kg−1,
pH=7.4)andsodiumphosphatebuffer-2(osmolality20mmol/kg−1 pH=7.4),acetonitrile,
methanol, n-hexane, and isopropanol (all gradient grade for chromatography, Merck) were
used. Other reagents including lithium carbonate were of analytical grade. Water was
deionizedwithaMiliQ(Milipore)apparatus.Allsolventsintheexperimentweredeoxidized
with a Polsonic ultrasonic cleaner.
Blood samples taken from eight different healthy adult subjects were supplied by the
Blood Donor Centre of Bialystok. The age of the donors varied between 20 and 50 years.
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515FIGURE 1 Isolation of erythrocyte membranes and phospholipid extraction.
Blood was treated with EDTA as an anticoagulant. The
procedural sequence of isolation of erythrocyte membranes
and extraction of phospholipids was performed in accordance
to Radin (1981) and Ostrowska et al. (2000) and is given in
Figure 1. The erythrocytes were incubated at 37◦Cf o r1hw i t h
10 mM lithium carbonate in the phosphate buffer-1. To prevent
the oxidation of phospholipids during extraction, 0.03% of
BHT was added, along with ﬂushing with nitrogen at each
step of the procedure. Separation and determination of isolated
phospholipidswereperformedbynormalphaseHPLCwithiso-
cratic elution. The mobile phase was acetonitrile-methanol-85%
phosphoric acid mixture of 130:5:1.5 volume ratio. The ﬂow
rate of the mobile phase was 1 mL/min−1. The chromatogram
was recorded at 214 nm wavelength (Ostrowska et al. 2000).
The peaks of phosphatidylinositol (PI), phosphatidylserine
(PS), phosphatidylethanolamine (PE), and phosphatidylcholine
(PC) are well separated. Unfortunately, sphingomyelin is not
determined under the selected conditions.
Statistical Analysis
The results are expressed as mean values ± SD (n = 8).
Statistically signiﬁcant differences were determined by the
Student’s t-test, as well as ANOVA. p ≤ 0.05 was considered
statistically signiﬁcant.
RESULTS AND DISCUSSION
These studies investigate the effect of lithium on phos-
pholipids of human erythrocyte membranes. Concentrations
of lithium above the therapeutic dose by half an order of
magnitude and in vitro experiments were undertaken. Results
areshowninFigure2.Theresultsclearlyindicatethestatistically
signiﬁcant decrease in PC content in erythrocytes due to
lithium in vitro treatment. This effect was predicted by Jenden
et al. (1980) and Hanin et al. (1980), but not observed in
in vivo experiments with persons treated with lithium (Pleul
and M¨ uller-Oearlinhausen 1986; Bramham and Riddell 1995).
Jenden et al. (1980) and simultaneously Hanin et al. (1980)
discovered 10 to 30 times higher choline levels in erythrocytes
treated with lithium and predicted that choline originates
FIGURE 2 Comparison of the phospholipid content of erythro-
cyte membranes as a percentage of the total phospholipids from
Li+-treated and Li+-untreated (control). ∗ Statistically signiﬁcant
differences for p ≤ 0.05 with respect to control.
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the difference between in vitro and in vivo experiments is
probably signiﬁcantly lower lithium concentrations in the in
vivo experiments and complex reactions involving lithium.
The other result of the research is an increase in PI content.
Although it is a surprising effect, the increase is statistically
signiﬁcant. A similar effect is observed in neuroblastoma
membranes during chronic Li+ treatment for 4 to 6 weeks
(Layden et al. 2005). This may be caused by the inhibition of PI
phosphorylation to PIP (phosphatidylinositol-4-phosphate) and
subsequently to PIP2 (phosphatidylinositol-4,5-bisphosphate),
which is the next stage in the PI cycle (Shaladubina at al.
2001). This is why PI is accumulated in membranes, since
the synthesis of PI is not inhibited but PI transformation is
stopped. Probably the inositol accumulation process could
be connected with the phosphatidilcholine decrease. Phos-
phatidilcholine undergoes hydrolysis into phosphatidic acid
and free choline. Then phosphatidic acid changes into the
form of diacylglicerol (DAG). DAG is converted into cytidine
diphosphate-diacylglycerol (CDP-DAG). CD-DAG could react
with inositol to form phosphatidylinositol (PI) (Shaladubina
et al. 2001; Murray et al. 1996).
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